QUIA PHARMA AB (FRA:99B0) 12-1 Month Momentum %: -66.67% (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is QUIA PHARMA AB 12-1 Month Momentum %?

QUIA PHARMA AB FRA:99B0 12-1 Month Momentum % is -66.67% as of Sep. 22, 2026. The stock has 3 warning signs investors should review.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-22), QUIA PHARMA AB's 12-1 Month Momentum % is -66.67%.

The industry rank for QUIA PHARMA AB's 12-1 Month Momentum % or its related term are showing as below:

FRA:99B0's 12-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -20.52 vs FRA:99B0: -66.67

QUIA PHARMA AB  (FRA:99B0) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

QUIA PHARMA AB 12-1 Month Momentum % Related Terms

FRA:99B0 vs VRTX, REGN, ALNY: 12-1 Month Momentum % Comparison

For the Biotechnology subindustry, QUIA PHARMA AB's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

QUIA PHARMA AB 12-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QUIA PHARMA AB's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where QUIA PHARMA AB's 12-1 Month Momentum % falls into.


QUIA PHARMA AB  (FRA:99B0) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -66.67% mean?
QUIA PHARMA AB (FRA:99B0) has a 12-1 Month Momentum % of -66.67% as of Sep. 22, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's 12-1 Month Momentum % too high?
QUIA PHARMA AB's current 12-1 Month Momentum % is -66.67%.
How does QUIA PHARMA AB's 12-1 Month Momentum % compare to VRTX and REGN?
QUIA PHARMA AB's 12-1 Month Momentum % of -66.67% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on QUIA PHARMA AB and its competitors. QUIA PHARMA AB's current 12-1 Month Momentum % is -66.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current 12-1 Month Momentum % of -66.67%. The current 12-1 Month Momentum % is -66.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current 12-1 Month Momentum % is -66.67% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

QUIA PHARMA AB Business Description

Address Virdings Alle 32 B, Uppsala, SWE, 754 50
Quia Pharma AB is a Swedish pharmaceutical development company built around its patented Uni-Qleaver drug delivery platform. The company uses this technology to create improved, patentable formulations of drugs that are either already approved or in clinical development, aiming to enhance their properties such as absorption, stability, or dosing. Alongside its pharmaceutical development activities, Quia Pharma operates a consumer health business, selling dietary supplement products including omega-3, astaxanthin, and collagen, which it markets internationally through online channels such as Amazon. The company generates revenue from these supplement sales while pursuing development partnerships and licensing opportunities for its drug delivery technology. Its operations span pharmaceutical research and development as well as direct-to-consumer e-commerce, with a geographic focus on the Nordic region and international online markets.